PURPOSE: Canine multifocal retinopathy (cmr) is an autosomal recessive disorder of multiple dog breeds. The disease shares a number of clinical and pathologic similarities with Best macular dystrophy (BMD), and cmr is proposed as a new large animal model for Best disease. METHODS: cmr was characterized by ophthalmoscopy and histopathology and compared with BMD-affected patients. BEST1 (alias VMD2), the bestrophin gene causally associated with BMD, was evaluated in the dog. Canine ortholog cDNA sequence was cloned and verified using RPE/choroid 5'- and 3'-RACE. Expression of the canine gene transcripts and protein was analyzed by Northern and Western blotting and immunocytochemistry. All exons and the flanking splice junctions were screened by direct sequencing. RESULTS: The clinical phenotype and pathology of cmr closely resemble lesions of BMD. Canine VMD2 spans 13.7 kb of genomic DNA on CFA18 and shows a high level of conservation among eukaryotes. The transcript is predominantly expressed in RPE/choroid and encodes bestrophin, a 580-amino acid protein of 66 kDa. Immunocytochemistry of normal canine retina demonstrated specific localization of protein to the RPE basolateral plasma membranes. Two disease-specific sequence alterations were identified in the canine VMD2 gene: a C(73)T stop mutation in cmr1 and a G(482)A missense mutation in cmr2. CONCLUSIONS: The authors propose these two spontaneous mutations in the canine VMD2 gene, which cause cmr, as the first naturally occurring animal model of BMD. Further development of the cmr models will permit elucidation of the complex molecular mechanism of these retinopathies and the development of potential therapies.
PURPOSE:Canine multifocal retinopathy (cmr) is an autosomal recessive disorder of multiple dog breeds. The disease shares a number of clinical and pathologic similarities with Best macular dystrophy (BMD), and cmr is proposed as a new large animal model for Best disease. METHODS: cmr was characterized by ophthalmoscopy and histopathology and compared with BMD-affected patients. BEST1 (alias VMD2), the bestrophin gene causally associated with BMD, was evaluated in the dog. Canine ortholog cDNA sequence was cloned and verified using RPE/choroid 5'- and 3'-RACE. Expression of the canine gene transcripts and protein was analyzed by Northern and Western blotting and immunocytochemistry. All exons and the flanking splice junctions were screened by direct sequencing. RESULTS: The clinical phenotype and pathology of cmr closely resemble lesions of BMD. CanineVMD2 spans 13.7 kb of genomic DNA on CFA18 and shows a high level of conservation among eukaryotes. The transcript is predominantly expressed in RPE/choroid and encodes bestrophin, a 580-amino acid protein of 66 kDa. Immunocytochemistry of normal canine retina demonstrated specific localization of protein to the RPE basolateral plasma membranes. Two disease-specific sequence alterations were identified in the canineVMD2 gene: a C(73)T stop mutation in cmr1 and a G(482)A missense mutation in cmr2. CONCLUSIONS: The authors propose these two spontaneous mutations in the canineVMD2 gene, which cause cmr, as the first naturally occurring animal model of BMD. Further development of the cmr models will permit elucidation of the complex molecular mechanism of these retinopathies and the development of potential therapies.
Authors: A D Marmorstein; L Y Marmorstein; M Rayborn; X Wang; J G Hollyfield; K Petrukhin Journal: Proc Natl Acad Sci U S A Date: 2000-11-07 Impact factor: 11.205
Authors: Artur V Cideciyan; Samuel G Jacobson; Tomas S Aleman; Danian Gu; Susan E Pearce-Kelling; Alexander Sumaroka; Gregory M Acland; Gustavo D Aguirre Journal: Proc Natl Acad Sci U S A Date: 2005-03-22 Impact factor: 11.205
Authors: F Krämer; K White; D Pauleikhoff; A Gehrig; L Passmore; A Rivera; G Rudolph; U Kellner; M Andrassi; B Lorenz; K Rohrschneider; A Blankenagel; B Jurklies; H Schilling; F Schütt; F G Holz; B H Weber Journal: Eur J Hum Genet Date: 2000-04 Impact factor: 4.246
Authors: P M D'Cruz; D Yasumura; J Weir; M T Matthes; H Abderrahim; M M LaVail; D Vollrath Journal: Hum Mol Genet Date: 2000-03-01 Impact factor: 6.150
Authors: James W Kijas; Artur V Cideciyan; Tomas S Aleman; Michael J Pianta; Susan E Pearce-Kelling; Brian J Miller; Samuel G Jacobson; Gustavo D Aguirre; Gregory M Acland Journal: Proc Natl Acad Sci U S A Date: 2002-04-23 Impact factor: 11.205
Authors: Sem Genini; Barbara Zangerl; Julianna Slavik; Gregory M Acland; William A Beltran; Gustavo D Aguirre Journal: Invest Ophthalmol Vis Sci Date: 2010-06-23 Impact factor: 4.799
Authors: Karina E Guziewicz; Julianna Slavik; Sarah J P Lindauer; Gustavo D Aguirre; Barbara Zangerl Journal: Invest Ophthalmol Vis Sci Date: 2011-06-23 Impact factor: 4.799
Authors: Adiv A Johnson; Karina E Guziewicz; C Justin Lee; Ravi C Kalathur; Jose S Pulido; Lihua Y Marmorstein; Alan D Marmorstein Journal: Prog Retin Eye Res Date: 2017-01-30 Impact factor: 21.198
Authors: Raghavi Sudharsan; Michael H Elliott; Natalia Dolgova; Gustavo D Aguirre; William A Beltran Journal: Adv Exp Med Biol Date: 2018 Impact factor: 2.622
Authors: Freya M Mowat; Simon M Petersen-Jones; Helen Williamson; David L Williams; Philip J Luthert; Robin R Ali; James W Bainbridge Journal: Mol Vis Date: 2008-12-29 Impact factor: 2.367